The IgG fraction of human anti-endothelial cell antibodies (AECA) obtained from a patient with Wegener's granulomatosis was used as immunogen to raise AECA mAb in mice selected among those which developed vasculitis-like lesions after immunization. Three mAb (BGM, 3C8 and 7G2), selected by cyto-ELISA and flow cytometry analyses, featured a specific reactivity with human umbilical vein endothelial cells (HUVEC) and the mouse endothelial cell line H5V; on the contrary, HEp2 cells, the murine melanoma B16 cell line, the extracellular matrix as well as several other antigens tested were not recognized. BGM mAb, an IgG3 precipitating a 70 kDa structure from HUVEC, was able to induce endothelial cells to secrete amounts of IL-6 significantly higher than irrelevant controls or mAb binding different endothelial antigens (i.e. CD31, CD29, ICAM-1 and HLA class I). BGM mAb induced significant levels of antibody-dependent cell cytotoxicity (13 ⍨ 2.5 versus 0.6 ⍨ 0.03%). To the best of our knowledge, BGM is the first murine mAb specific for human endothelial cells generated by idiotypic manipulation; secondly, its biological properties further support the notion of a pathogenic role for AECA in autoimmune-mediated diseases.
Introduction
Anti-endothelial cell antibodies (AECA) are recognized as serological markers of several autoimmune and non-autoimmune human diseases, some of which are clearly characterized by immune-mediated vascular damage (1) (2) (3) . AECA are also detected in sera of mice with spontaneous or experimentally induced autoimmune-like diseases (e.g. vasculitis) (4, 5) . The antigens recognized by these antibodies range from 25 to 200 kDa, likely reflecting the complexity of surface proteins expressed by endothelial cells (5) (6) (7) (8) .
It is difficult to draw definitive conclusions about nature and specificities of these autoantibodies, due primarily to the lack of standardization among the detection methods used (e.g.
Correspondence to: Y. Shoenfeld Transmitting editor: I. Pecht Received 13 January 1998, accepted 9 March 1998 cyto-ELISA, standard microcytotoxicity, flow cytometry, Western blotting and immunoprecipitation) (9) . A central issue is whether AECA are capable of inducing tissue damage or whether they rather represent an epiphenomenon of a previously induced vascular insult. The debate has intensified following in vitro observations documenting endothelial cell activation and expression of adhesion molecules by AECA from patients with Wegener's granulomatosis (WG) and scleroderma (10, 11) . Further, there are reports that vasculitis-like lesions are associated with murine AECA, induced by immunizing naive mice with IgG fractions from WG patients (5).
Recently we provided additional support for the pathogenic role of AECA in an experimental model of idiotypically induced vasculitis (12) . Indeed, we used a preparation of an AECAreactive IgG-enriched fraction from a patient with WG and depleted of anti-proteinase 3 (PR3) activity for immunizing a panel of mice. Detectable levels of anti-AECA (Ab2) produced by mice were thus followed by development of anti-anti-AECA (Ab3), displaying binding properties similar to the original human AECA. Development of Ab3 was associated with infiltration of lymphoid cells around arterioles and venules as well as deposition of Ig at the outer part of blood vessel walls of the mice. The known model of AECA-associated vasculitis-like lesions was our starting point to raise and characterize murine AECA mAb. These mAb could provide unique tools for studying the pathogenetic potential of AECA, both in in vitro and in vivo experimental models (13) (14) (15) (16) (17) (18) .
Methods

Human IgG purification
Human AECA were prepared using post-plasmapheresis material from a patient with active, biopsy-proven WG displaying a high level of AECA (5). Aliquots of 10 ml of plasma were applied on a 5 ml Protein G-Sepharose column (Pharmacia, Uppsala, Sweden) and total IgG was affinity purified as previously detailed (10) . The final protein concentration of IgG fraction was 1.2 mg/ml.
Absorption of anti-PR3 activity PR3 was purified as previously detailed (19) . Briefly, 800 µl of purified PR3 (20 mg/ml in 0.2 M NaHCO 3 , 0.5 M NaCl, pH 8.3) were coupled to N-hydroxy-succinimide activated matrix [1 ml HI-TRAP NHS-activated column (Pharmacia). The final coupling efficiency was 67.4%. Anti-PR3 activity of WG IgG fraction (2 ml) was depleted by affinity chromatography on 1 ml column of immobilized human PR3 as previously described (10) . Anti-PR3 and AECA activity were measured before and after absorption as described (10) .
Mice BALB/c female mice 8-12 weeks of age were purchased from the Tel-Aviv University repository.
Immunization protocol
Mice were immunized with human AECA-enriched IgG fraction depleted of the anti-PR3 activity (10 mg/mouse in complete Freund's adjuvant, intradermally into the hind footpad). After 3 weeks, mice were boosted with 10 mg/mouse AECA-IgG in PBS. Splenocytes from mice displaying high levels of murine AECA activity were used for hybridoma preparation.
Production of mouse AECA mAb
Mouse AECA mAb were raised by fusion of splenocytes derived from AECA-positive mice with a mouse non-secreting myeloma line (NSO) using 41% polyethylene glycol. Cells (2ϫ10 5 cells/ well) were then plated with HAT selective medium in 96-well plates (Nunc, Roskilde, Denmark). Supernatants from growing hybridomas were screened for specific mAb production by cyto-ELISA, using human and mouse endothelial cells. Positive hybridomas obtained after three limiting dilutions served as the source for mAb. Mouse IgG subclasses were determined by rat anti-mouse Ig subclass mAb (PharMingen, San Diego, CA). Cell supernatant from BGM clone was precipitated with (NH 4 ) 2 SO 4 and after dialysis applied on an anti-mouse IgG affinity column (Sigma, St Louis, MO). After extensive washes, the bound material was eluted by 0.5 M Tris-HCl, pH 2.5, and then dialyzed against PBS.
Endothelial cell cultures and AECA assay Human umbilical vein endothelial cells (HUVEC) were isolated from normal term umbilical cord veins by collagenase perfusion and cultured under standard conditions (10) . A pool of HUVEC (obtained from at least three different donors) at the first passage was used for all the experiments. H5V, a polyoma middlesized T antigen-transformed mouse heart endothelial cell line (20) , was grown in DMEM medium (Flow, Irvine, UK) supplemented with 10% FCS (Flow) and used for cyto-ELISA. AECA were detected by ELISA on confluent living cells as previously described (10) .
Anti-matrix antibodies ELISA
For detection of anti-matrix antibodies, resting HUVEC (5ϫ10 4 cells/well) at the first passage were plated in 96-well microtiter plates (Nunc) precoated with 0.1% gelatine and grown to a confluent monolayer. Cells were then washed twice with HBSS (Flow) and successively detached by incubation with 30 mM EDTA in HBSS (Ca 2ϩ -and Mg 2ϩ -free) for 15 min at 37°C. After washing, the plates were blocked by adding 200 ml/well of HBSS/0.05% BSA (Sigma) for 1 h at 37°C. Following additional washings, the supernatants of mouse hybridomas or purified IgG were incubated for 2h at room temperature and bound antibodies detected using alkaline phosphatase-conjugated goat anti-mouse IgG (Jackson ImmunoResearch, West Grove, PA) followed by the addition of p-nitrophenyl phosphate disodium (pNP, Sigma) in 0.05 M NaHCO, pH 9.8, as a substrate. The optical density values were read at 405 nm in a semiautomatic Titertek Elisa reader.
HEp2 and B16 cell line-ELISA HEp2 hepitelioma and B16 melanoma cells were placed in 96-well plates (Nunc) at 5ϫ10 4 cells/well and used for hybridoma screening when the confluent monolayer was formed. Antibody binding was assayed by a cell solid-phase ELISA as detailed above.
FACS analysis
Both HUVEC at the first passage and H5V cells were used for cytofluorimetric studies after recovery from the culture flasks with 30 mM EDTA for 10 min at 37°C. Cells were then resuspended in 1.0 ml PBS/2% FCS and 0.1% NaN 3 and incubated for 30 min at 4°C with murine mAb. Cells were extensively washed with PBS/0.1% NaN 3 , incubated with FITC-conjugated goat anti-mouse IgG (Sigma) for 20 min at 4°C, washed and analyzed with a Coulter Epics flow cytometer.
Immunoprecipitation of the BGM antigen HUVEC (2ϫ10 7 cells) were washed in ice-cold PBS and surface labeled with 125 I (Amersham, Amersham, UK) using the lactoperoxidase method. After three washes with 2 mM NaI, cells were lysed using RIPA buffer (150 mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl pH 8.0, 1 mM phenylmethylsulfonyl fluoride). Samples were subsequently precleared by means of an irrelevant mAb conjugated to goat anti-mouse IgG-agarose (Sigma). Anti-mouse IgG-agarose beads conjugated either to BGM mAb or isotype-matched control CBT8 (anti-CD8) (21) were then added to the lysate and incubated overnight. Beads were then washed 3 times with lysis buffer, and immune complexes extracted by boiling in SDS sample buffer and run on a 8% SDS-PAGE. The gel was then dried and exposed for autoradiography to Kodak X-Omat AR film.
IL-6 production by endothelial cells
The confluent monolayer of HUVEC in 96-well plates was incubated for 24 h with serial concentrations of purified AECA mAb or control mAb at a final volume of 200 ml/well (in culture medium). Plates were then centrifuged at 800 r.p.m. at 4°C for 10 min and cell-free supernatants used for IL-6 determination. Supernatants from HUVEC incubated with 10 U/ml of recombinant human IL-1b (British BioTechnology, Oxford, UK) were used as positive controls. The level of IL-6 was measured as hybridoma growth factor on the indicator 7DT1 cell line as previously reported (10) . Briefly, 2ϫ10 3 cells in 200 ml medium (four replicates/sample) were incubated for 72 h with the appropriate supernatants to be tested. The number of cells was assessed by the 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide colorimetric test. Recombinant human IL-6 kindly provided by Dr S. Gills (Immunex, Seattle, WA) was used as the reference standard. (The level of IL-6 in the tested supernatants was expressed as U/ml.) In the same experimental conditions, mouse mAb directed against different endothelial surface antigens, i.e. CD31 (22) , CD29 (22) , ICAM-1 (Serotec, Kidlington, UK) and HLA class I (22), were tested for their ability to induce secretion of IL-6, using an ELISA kit (Amersham) (and expressed as pg/ml).
Cytotoxicity assays
Antibody-and complement-dependent cytotoxicity were evaluated as previously described in detail (23) . Briefly, confluent 51 Cr radiolabeled HUVEC monolayers were incubated for 1 h at 37°C with serial protein concentrations of BGM or of anti-HLA class I mAb IgG2a (W6/32; Serotec) or of an irrelevant murine IgG2a mAb. After extensive washes with HBSS, the monolayers were incubated for 2 h with mouse fresh serum or human AB fresh serum as source of complement (12.5 ml/well). Then the plates were centrifuged at 1500 g for 5 min and 100 ml of cell supernatants were collected and the radioactivity measured in a γ-counter. The results were expressed as percentage of induced 51 Cr-specific release, using the formula ϭ experimental c.p.m. -spontaneous c.p.m./maximal c.p.m. -spontaneous c.p.m. Maximal release of radioactivity was achieved after addition of 100 ml of lytic buffer (0.1% SDS, 25 mM NaOH) and spontaneous radioactivity was evaluated in the supernatant from HUVEC cultured in medium alone. Anti-HLA class I mAb gave specific 51 Cr-specific release values of 35 Ϯ 7% (mean values Ϯ SD of triplicate experiments). Antibodydependent cell cytotoxicity (ADCC) analysis was performed by adding normal human peripheral blood mononuclear cells (PBMC) at an effector:target ratio of 50:1 to 51 Cr-labeled HUVEC monolayers preincubated with different concentrations of murine AECA mAb. Radioactivity in the supernatants was calculated as detailed above.
Results
Absorption of anti-PR3 activity from WG patient IgG
The anti-PR3 activity of total plasma IgG was depleted by absorption on PR3 immobilized on a HI-TRAP NHS-activated column. After passage through the column, unbound material was completely free of detectable anti-PR3 activity: mean OD Ϯ SD values were 0.866 Ϯ 0.154 versus 0.107 Ϯ 0.090 before and after absorption respectively. After depletion of anti-PR3 antibodies, the affinity-purified IgG fraction still exhibited strong AECA activity (Fig. 1 ).
Production and screening of murine AECA mAb Twelve primary cultures derived from two distinct fusions were identified as AECA specific by initial cyto-ELISA screening, using unfixed HUVEC and H5V cells. The mAb production in three of these primary cultures (BGM, 3C8 and 7G2) was rendered monoclonal and stable after three rounds of growth in conditions of limiting dilution. Table 1 reports the results of the immunoreactivity of the mAb by ELISA against a panel of different antigens. The selected AECA mAb showed a restricted reactivity with HUVEC and H5V, and no reactivity with HEp2 or B16 lines, extracellular matrix or other antigens tested. Interestingly, the reaction of BGM mAb (an IgG3 isotype) was significantly stronger with HUVEC than with H5V cell line. Figure  2 shows binding characteristics on HUVEC exerted by purified BGM mAb in serial dilutions.
Cytofluorography analysis of mAb reactivity Figure 3 shows the cytofluorographic profiles obtained by reacting BGM mAb with HUVEC. All the selected mAb were strongly reactive with HUVEC; mainly BGM, with a resulting score of 95.7% of cells stained. Comparative FACS analysis of three mAb on HUVEC and H5V cell line (Fig. 4) reiterated the higher reactivity of BGM with human endothelial cells. Immunoprecipitation HUVEC were surface-labeled with 125 I and lysed with RIPA buffer. The target molecule was immunoprecipitated with BGM mAb, and the immune complexes dissociated by boiling and run on a 8% SDS-PAGE, which showed a band of M r~7 0 kDa, both under reducing and non-reducing conditions ( Fig. 5 ; nonreducing condition not shown). No band was precipitated under the same conditions by an irrelevant isotype-matched control mAb.
Effects of murine AECA mAb on IL-6 secretion HUVEC cultured 24 h in the presence of serial concentrations of BGM mAb released dose-dependent amounts of IL-6 (Table  2) , as compared to background levels obtained by using an irrelevant mAb. Endotoxin contamination of the mAb was ruled out by performing parallel experiments in the presence of polymyxine B (5 µg/ml). The addition of the antibiotic did not affect IL-6 secretion, suggesting that endotoxin levels did not play a significant role in the HUVEC activation by mAb (Table 2) . Separate experiments were devised to answer the question whether the binding of murine mAb specific for known HUVEC surface antigens (i.e. CD31, CD29, ICAM-1 and HLA class I) by itself were able to induce secretion of IL-6. In spite of a strong binding to HUVEC, none of these mAb induced an IL-6 secretion comparable to BGM mAb (Tables 3 and 4) .
Cytotoxic activity performed by AECA mAb The direct addition of the BGM mAb to 51 Cr-labeled HUVEC both in the presence and absence of fresh complement did not produce any significant cytotoxic effect. The co-cultivation of human PBMC with HUVEC internally labeled with 51 Cr and presensitized with BGM mAb was followed by a specific release of 13% of the radioactivity versus 0.6% for cells preincubated with control mAb (Table 5) .
Discussion
This paper describes an attempt to study the antigenic repertoire recognized by human antibodies in autoimmune- 
Values are expressed as OD mean values Ϯ SD of triplicate experiments. 
Values are expressed as pg/ml of IL-6 (mean Ϯ SD of triplicate experiments) evaluated by a solid phase ELISA (see Methods).
As a positive control, HUVEC cultured in the presence of 10 U/ml of human recombinant IL-1β induced production of 1076 Ϯ 289 pg/ml of IL-6. mediated diseases by reconstructing the internal image of the target with murine mAb. In detail, murine mAb reactive with HUVEC were raised after idiotypic manipulation of the repertoire of naive mice by using as an immunogen AECA obtained from a WG patient. The method used to generate such mAb exploits a dysregulation of the murine idiotypic network (24) , where the immunization with a given 'pathogenic idiotype' (Ab1) is followed by the production of murine antiidiotypic antibodies (Ab2) bearing the internal image of the Ab used for injection. The disrupted idiotypic network yields antibodies against Ab2 (anti-anti-idiotypic ϭ Ab3) bearing similar binding properties to the starting antibodies (Ab1). The murine antibodies induced following this procedure displayed associations with pathological findings similar to those reported in the analogous human autoimmune disease, characterized by AECA autoantibodies (12) (13) (14) (15) (16) (17) (18) (24) (25) (26) (27) . Accordingly, the injection of WG IgG with absent anti-PR3 activity induces the appearance of murine AECA antibodies in naive mice. Such autoantibodies were associated with the presence of histopathological signs of a vasculitic process (12) . The murine AECA mAb obtained in the present study are likely to be representative of the Ab3 population found in the experimental models, and bear structural and relevant functional similarities with the WG IgG used for the immunization. Indeed, such AECA mAb react with surface endothelial antigens that might be available for circulating AECA in mice. Moreover, and in line with previous findings on human AECA autoantibodies, such mAb featured a reactivity almost exclusive for HUVEC. The molecules bearing the epitopes recognized by the AECA mAb were not expressed by human and murine non-endothelial cells as well as by the endothelial cell matrix. The reactivity of the AECA mAb with HUVEC is further confirmed by its ability to precipitate a surface molecule of M r~7 0 kDa. A band with comparable M r was obtained also by using as precipitating agent either polyclonal Ig from WG patients enriched with AECA or mice with AECA-associated vasculitis experimentally induced (5, 8) . These findings support the hypothesis that the specific idiotype of the original human AECA IgG used for the immunization is instrumental in driving the immune response of the animals. In addition, the occurrence of histological signs of vessel inflammation in mice with antibodies against the endothelial 70 kDa antigen as well as the presence of a comparable reactivity associated with spontaneous AECA in human pathology suggest that this so far unknown molecule might represent a critical target to sustain the vessel injury.
BGM mAb displays biological effects comparable with those previously reported for polyclonal AECA IgG fractions spontaneously occurring in WG patients (10) . Although not cytotoxic alone or in the presence of fresh complement, the AECA mAb were indeed able to mediate an ADCC to HUVEC monolayers. Furthermore, AECA mAb induced HUVEC to activate, as witnessed by up-regulatory effects on IL-6 secreted by HUVEC. Both binding activity as well as functional effects on endothelial cells appear to be mediated by high mAb concentrations that might be related to a low cell surface expression of the antigenic target. The array of such biological activities might be important to mediate endothelial cell damage and/or to favor recruitment and activation of PBMC in the vessel walls, a behavior reported in mice with AECAassociated vasculitis induced experimentally (12) . The ability of the murine AECA autoantibodies to activate HUVEC monolayers in vitro seems of biological relevance, mAb directed against constitutive surface endothelial molecules (e.g., CD31, CD29, ICAM-1 and HLA class I) not significantly affecting IL-6 secretion. A possibility is that AECA mAb induce activation signals either directly or through the cross-linking of cell surface molecules as previously suggested for polyclonal AECA IgG from WG sera (10) . The AECA mAb here generated from mice with AECA-associated lesions were similar to those of vasculitis and this observation adds new evidence to the pathogenic role of anti-endothelial antibodies in this experimental animal models.
Despite their identification 25 years ago (28, 29) , the precise specificities and biological activities of AECA are not yet fully understood. The uncertainty stems from the nature of antigens expressed on endothelial cells, nearly all of which could represent potential epitopes recognized by AECA. As a further complication, AECA have been detected in a wide variety of associated diseases (reviewed in 2). The study of the global pathogenic potential of AECA is concentrated in two principal directions: some in vitro experimental models indicate that human AECA are capable of inducing endothelial cell activation (10, 11, 30, 31) and elevated tissue factor expression (32). Further evidence pointing towards possible pathogenicity of AECA derives from in vivo models in which direct glomerular tissue injury have been associated with the appearance of murine AECA (12, 33) . The current study provides a starting point through the establishment of a murine mAb employing idiotypic manipulation. Generation of murine AECA mAb from mice with experimentally-induced AECA vasculitis will be useful in elucidating some of the influences of antibodies on endothelial cells in in vivo assays. These goals could be accomplished either by active immunization of mice with the AECA mAb or by passively infusing the mAb i.v. and evaluating the animals for possible markers of vasculitis.
